FLUIDIGM CORPORATION (NASDAQ:FLDM) Files An 8-K Other Events
Item 8.01.Other Events.
From February 21, 2019 through February 27, 2019, Fluidigm Corporation (the “Company”) received notices from holders of its 2.75% Exchange Convertible Senior Notes due 2034 (the “Senior Convertible Notes”) electing to voluntarily convert approximately $21.9 million in aggregate principal amount of Senior Convertible Notes to the terms of the Second Supplemental Indenture dated March 6, 2018, between the Company and U.S. Bank National Association (the “Trustee”) to the Indenture dated as of February 14, 2014, by and between the Company and the Trustee. As a result of such voluntary conversions, the Company has elected to fully satisfy its conversion obligations by delivering 2,843,029 shares of the Company’s common stock to such holders voluntarily converting their Senior Convertible Notes and has retired $21,933,000 of Senior Convertible Notes, bringing the aggregate principal amount of Senior Convertible Notes retired as of February 27, 2019 to $138,082,000.
On February 27, 2019, the Company notified the Trustee of the Company’s intention to exercise its Issuer’s Conversion Option to the terms of the Second Supplemental Indenture with respect to the remaining approximately $11.9 million in aggregate principal amount of Senior Convertible Notes.
About FLUIDIGM CORPORATION (NASDAQ:FLDM)
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
